Becton, Dickinson and Company (BDX)

BDX stock is trading near $145 — we rate Becton Dickinson an accumulate-on-weakness Buy with a $189 average analyst price target, after the company beat Q2 2026 adjusted EPS, raised full-year guidance, and printed a 24.2% adjusted operating margin despite a 160-bps tariff drag. If Becton Dickinson j…

In early May 2026, Becton, Dickinson and Company reported fiscal second-quarter sales of US$4,714 million but swung to a net loss of US$311 million, while reaffirming low single-digit plus GAAP revenue growth guidance for the full year and later appointing seasoned healthcare executive Peter ...

The subdued stock price reaction suggests that Becton, Dickinson and Company's ( NYSE:BDX ) strong earnings didn't...

Becton Dickinson has reported fresh quarterly figures and updated its outlook, drawing investor attention to the medical technology specialist’s growth drivers in diagnostics and diabetes care.

Separately, BD’s 10-Q discussed ... to the earnings outlook. ... BD Investor Relations, U.S. SEC, Stock Analysis · Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes. $BDX insiders have ...